(Reuters) – Stryker Corp posted an upbeat second-quarter profit on Tuesday, as demand for its medical and surgical devices rose, driven by growth in non-urgent surgeries.
On an adjusted basis, the company reported a profit of $2.81 per share for the quarter ended June 30, slightly above analysts’ estimates of $2.79 per share.
The joint-implant maker also raised its annual profit per share guidance to betweeen $11.9 and $12.1 from previous range of $11.85 to $12.05. The average Wall Street estimate for 2024 profit is $11.95 per share, according to LSEG data.
Demand for medical implant devices has surged since last November, as more people have opted for surgical treatments that were deferred during the pandemic, leading to an increase in procedural volumes.
Sales at Stryker’s medical surgery and neurotechnology unit rose 9% to $3.1 billion, while sales in the orthopedics and spine segment rose 7.9% to $2.3 billion.
The Michigan-based company, which offers implants for joint replacement, trauma and spine-based surgeries, surgical equipment, among other products, now expects 2024 organic net sales growth to be in the range of 9% to 10%, higher than its previous forecast of 8.5% to 9.5%.
The company reported a 8.5% rise in quarterly revenue to $5.4 billion, in line with LSEG estimates of $5.41 billion.
(Reporting by Unnamalai L in Bengaluru; Editing by Tasim Zahid)
Comments